Live
- MEIL dispatches refinery equipment for Mongolia
- 265 SCTPCs take oath in Rachakonda
- Commissioner CV Anand urges dedication as 747 SCTPCs take oath
- 270 trainee PCs passing-out parade held at Cyberabad
- Beware of bacterial predators
- Empowering youth for Viksit Bharat
- Antibiotic Awareness Week (Nov. 18-24): Beware of bacterial predators
- MyVoice: Views of our readers 22nd November 2024
- Young Leaders Dialogue: Empowering youth for Viksit Bharat
- Drug abuse eating into vitals of our nation
AstraZeneca resumes Coronavirus vaccine trials in UK
Coronavirus vaccine
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
New Delhi: Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
On September 6, the standard review process had triggered a voluntary pause to vaccination across all global trials to allow the review of safety data by independent committees and international regulators.
The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume, AstraZeneca said on Saturday.
"AstraZeneca and the University of Oxford as the trial sponsor cannot disclose further medical information. All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," it added.
AstraZeneca is committed to the safety of the trial participants and the highest standards of conduct in clinical trials.
"The company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic," the company said.
AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.
After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
